Wegovy, Ozempic, Rybelsus (Semaglutide) the Champix of Alcohol Cessation - Stop Drinking

Wegovy, Ozempic, Rybelsus: (Active ingredient: Semaglutide), affects the brain’s reward system, specifically the nucleus accumbens area, part of the limbic system. By blocking the release of dopamine, a neurotransmitter associated with alcohol-induced reward, the medication interferes with the brain’s response to alcohol. This finding suggests that reduced alcohol-induced premium plays a role in the medication’s effectiveness.

Semaglutide, could be the Champix of Alcohol Cessation - to help stop drinking.

This could also explain why the drug is so successful at weight loss:

• Alcohol and Weight Gain Go Hand in Hand
• Drinking Tends to Cause an Increased Appetite and Poor Diet Decisions
• Heavy Drinking Can Alter Your Fat Distribution
• Alcohol Can Slow Down Your Ability to Burn Fat
• Alcohol Can Impair Your Liver’s Ability to Function Properly
• Alcohol Wreaks Havoc on Your Hormones
• Drinking Disrupts Your Ability to Sleep Well

A recent study by Elisabet Jerlhag Holm and Cajsa Aranäs from the University of Gothenburg explored the mechanisms behind reducing alcohol consumption with a particular medication. 

Alcohol consumption is a prevalent behavior that has significant implications for public health, as excessive drinking is associated with various adverse effects, including an increased risk of chronic diseases. For individuals with diabetes, managing alcohol intake becomes even more crucial due to potential interactions with glucose control and complications.

Cajsa Aranäs doctoral student at Sahlgrenska Academy at the University of Gothenburg, who is responsible for much of the work behind the study presented here, said, “Alcohol activates the brain’s reward system, resulting in the release of dopamine, something that is seen in both humans and animals. This process is blocked by the medication in mice, and with our interpretation, this could cause a reduction in the alcohol-induced reward.” 

Semaglutide, sold as Ozempic, is in high demand due to its approval for treating obesity. Procurement challenges have arisen recently. Patients have reported reduced alcohol cravings after starting the medication. Current alcohol dependence treatment involves psychosocial methods and approved medicines. However, additional treatment options are needed due to the varied efficacy of existing medicines.

Semaglutide, a once-weekly tablet acting on the GLP-1 receptor, has shown promising results in reducing alcohol consumption and relapses in alcohol-dependent rats. A study published revealed that Semaglutide significantly reduced alcohol intake, with treated rats consuming half as much alcohol as untreated rats. Notably, the medication demonstrated equal effectiveness in both male and female rats.